Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950592 | 1.00 | NPC1 (0.34) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2926048 | 0.95 | LMNA (0.34) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL4539304 | 0.93 | LMNA (0.33) | LMNAPKMALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1040142 | 0.93 | LMNA (0.33) | LMNAPKMALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2920405 | 0.92 | FKBP1A (0.36) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2922334 | 0.92 | NPC1 (0.35) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2919070 | 0.92 | CASP3 (0.39) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2917136 | 0.92 | NPC1 (0.35) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2919704 | 0.92 | NPC1 (0.35) | NPC1LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL3465107 | 0.91 | LMNA (0.36) | NPC1LMNAPKMALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1897879-A2 | 2,4,5 substituted piperidines as renin inhibitors | Speedel Experimenta AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | NPC1 3393/4885LMNA 655/4885PKM 1874/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | NPC1 1614/4885LMNA 2502/4885PKM 1363/4885 |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | NPC1 1191/4885LMNA 948/4885PKM 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.